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 Therapeutic designs 
have failed 
Lack of connection 
between AD 
pathways 
Biomarkers gained 
importance in 
defining MCI: new 
therapeutic window 
• Alzheiŵer’s disease (AD) is a common, irreversible subtype of dementia in industrialized countries and characterized by the progressive appearance of 
abnormalities in biomarkers before its symptoms. 
• Pre-clinical diagnosis is the key to a better efficiency in treatments when administrated. 
• However, biomarkers have shown a more important role in subject stratification rather than the identification of subjects prone to develop AD.  
• A future standardization of these to enhance clinical essays and the development of new drugs is considered a medical need. 
 
ABSTRACT 
Cholinesterase Inhibitors [3] 
 
•  Donezepile 
•  Rivastagmine 
•  Galantamine 
 
NMDA-R antagonist [3] 
 
• Memantine  
 
Randomized, multicenter,double-blind, placebo-controlled Phase III (-) trials (2014)[2] 
Anti-Amyloid  Agreggant Agents[3] 
• Tramiprosat (Phase III) (-) 
• Colostrinina (Phase II) (±)                
• Scyllo-Inositol (Phase II) (±) 
 
Chelants 
• PTB2 (Phase IIa) (+) 
 
γ-secretase inhibitors  
• Semagacestat (Phase III) (-) 
• Tarenflurbil (Phase II) (-) 
• Avagacestat (Phase II) (-) 
 
β-secretase inhibitors 
• CST-21166 (Phase I) (+) 
 
α-secretase inhibitors  
• Etazolate (Phase IIa) (+) 
DRUGS AGAINST 
AMYLOID 
DEPOSITION 
PASSIVE IMMUNE THERAPY:  
MONOCLONAL ANTIBODIES 
• Therapeutic trials should be focused on early stages, requiring more 
diagnosis tools. New diagnostic criteria based on biomarkers has 
provided a new  therapeutic window for detection in early stages. 
• Even though amyloid positivity is a good marker on identifying 
subjects, actual studies with PET and CSF are difficult to standardize 
globally. So new positivity measures are needed. 
• Evidence of target engagement in SNC and evidence of downstream 
effects on relevant biomarkers may be established,  
• As a result of Phase III trials failure, new trial designs, including 
adaptive and targeted designs, should be explored.  
•  Target  Nt  •  Phase II: 
• Not improve cognition or function  
    significantly  + vasogenic edema 
• ↓ fibrilar Aβ accuŵulatioŶ ;PETͿ 
• Apoε4 - : ↓ ARIA-E + apparent treatment  
effect 
• Target  epitope in the middle • Phase III:  • Targeting Aβ has a positive effect oŶ 
cognition (although no biomarker changes 
for treatment effect) 
• ↓ cogŶitive decliŶe stable for 80 weeks 
• ↑ iŶ total CSF aŶd ↓CSF levels Aβ1-40 
• Mild-to-moderate subjects, targetting Aβ. 
 
What we have learned about Phase III trails? [2] 
 
• Value of stratifying participants 
• Biomarker and structural neuroimaging studies in Aβ - subjects are needed 
• Amyloid removal alone may not be sufficient to slow AD progression 
• Targeted trials are useful in AD, but  new approaches are needed 
• Phase II should  be larger to a more definitive clinical efficacy signal 
[Aβ1-42] [t-tau] [p-tau] 
 
CSF 
Amyloid fibrils deposition 
 
FDG-PET 
MRI 
Regional atrophy 
 
BAPINEUZUMAB 
 
SOLANEZUMAB 
 
CURRENT 
TREATMENT 
DISCUSSION 
REFERENCES 
MAIN ROLE OF 
BIOMARKER PROFILES 
• Defining populations  
 
• Confirming target access 
 
• Identifying AD at earlier stages  
and reflecting pathogenic process 
 
• Assessment of treatment effects 
and clinical status improvement   
Fig 1. Obtained and adapted from Lista S et al., J Nutr Health Aging (2015)[1,4]  
Fig 2. Effect of Solanezumab in human brain 
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(+) Promising results, (-)  Disappointing results (±) Doubtful results / Nt : N-terminal / CSF: cerebrospinal fluid / 
 Aβ : Amyloid- β/ FDG-PET: Fludeoxydeglucose- Positron Emission Tomography / MCI: Magnetic Ressonance 
Imaging/ ARIA-E: Amyloid-Related Imaging Abnormalities-Edema/ Apoε4: Apolipoprotein ε4 allele 
 
 
